SEARCH

SEARCH BY CITATION

References

  • 1
    Uribe-Botero G, Russell WO, Sutow WW, Martin RG. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol 1977; 67: 42735.
  • 2
    Bielack SS, Kempf-Bielack B, Delling G et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20 (3): 77690.
  • 3
    Meyers PA, Schwartz CL, Krailo M et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23 (9): 200411.
  • 4
    Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134: 28197.
  • 5
    Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007; 19: 3416.
  • 6
    Tomescu O, Barr FG. Chromosomal translocations in sarcomas: prospects for therapy. Trends Mol Med 2001; 7 (12): 5549.
  • 7
    Busam KJ, Fletcher CD. The clinical role of molecular genetics in soft tissue tumor pathology. Cancer Metastasis Rev 1997; 2: 20727.
  • 8
    Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003; 145: 130.
  • 9
    Fuchs N, Winkler K. Osteosarcoma. Curr Opin Oncol 1993; 5 (4): 66771.
  • 10
    Toguchida J, Yamaguchi T, Ritchie B et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52 (22): 61949.
  • 11
    Johnson SA, Hunter T. Kinomics: methods for deciphering the kinome. Nat Methods 2005; 2: 1725.
  • 12
    Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 2: 296313.
  • 13
    Ghoreschi K, Laurence A, O’Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009; 10: 35660.
  • 14
    Yamaguchi U, Nakayama R, Honda K et al. Distinct gene expression-defined classes of gastrointestinal stromal tumor. J Clin Oncol 2008; 26 (25): 41008.
  • 15
    Honda K, Yamada T, Hayashida Y et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005; 128: 5162.
  • 16
    Shitashige M, Naishiro Y, Idogawa M et al. Involvement of splicing factor-1 in β-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing. Gastroenterology 2007; 132 (3): 103954.
  • 17
    Van Vugt MA, Van De Weerdt BC, Vader G et al. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 2004; 279: 3684154.
  • 18
    Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17: 31622.
  • 19
    Whitehurst AW, Bodemann BO, Cardenas J et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446 (7137): 8159.
  • 20
    Schlabach MR, Luo J, Solimini NL et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319 (5863): 6204.
  • 21
    Golsteyn RM, Schultz SJ, Bartek J, Ziemiecki A, Ried T, Nigg EA. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994; 107 (Pt 6): 150917.
  • 22
    Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 32130.
  • 23
    Hamanaka R, Maloid S, Smith MR, O’Connell CD, Longo DL, Ferris DK. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994; 5: 24957.
  • 24
    Holtrich U, Wolf G, Brauninger A et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A 1994; 91 (5): 173640.
  • 25
    Knecht R, Oberhauser C, Strebhardt K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer 2000; 89: 5356.
  • 26
    Takahashi T, Sano B, Nagata T et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003; 94: 14852.
  • 27
    Weichert W, Denkert C, Schmidt M et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004; 90 (4): 81521.
  • 28
    Wolf G, Elez R, Doermer A et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997; 14: 5439.
  • 29
    Ahr A, Karn T, Solbach C et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002; 359 (9301): 1312.
  • 30
    Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002; 29 (6): 3548.
  • 31
    Sumara I, Gimenez-Abian JF, Gerlich D et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004; 14: 171222.
  • 32
    Gumireddy K, Reddy MV, Cosenza SC et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7: 27586.
  • 33
    Mross K, Frost A, Steinbild S et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008; 26: 55117.
  • 34
    Jimeno A, Li J, Messersmith WA et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008; 26 (34): 550410.